

# BRIDGING METABOLIC AND HEPATIC PATHWAYS IN MASH:

Mechanisms, Emerging Therapies,  
and Diagnostic Strategies

**TUESDAY, MAY 12, 2026**

16:15 – 17:45 TRT Time

**VENUE:**

Istanbul Congress Center (ICC) • Meeting Room: Hall 2

**FEATURES: 1.5 CME CREDITS**

- Interactive, case-based learning environment • Downloadable animations
- Create your own personalized poster



## FACULTY

**Prof. Vlad Ratziu, MD, PhD**  
 Professor of Hepatology  
 Sorbonne University  
 Pitié-Salpêtrière Hospital  
 Paris, France

## AGENDA

- I. Strategies for Prompt Screening, Recognition, and Diagnosis of Metabolic Conditions**
  - a) Pathophysiology of MASH
  - b) Risk factors and comorbidities
  - c) Guidelines for diagnosis and risk stratification
- II. Clinical Data for Current & Emerging Treatments for MASH/MAFLD**
  - a) Current FDA- & EMA-approved therapies
  - b) Investigational incretin-based agents
  - c) Other agents
- III. Case Discussions**

## EDUCATIONAL OBJECTIVES

- Describe the role of metabolic dysfunction and obesity on steatohepatitis and the reciprocal impact of liver health on metabolic regulation, including the importance of weight loss for improving patient outcomes and quality of life with MASLD/MASH
- Apply the mechanism of action of GCGR/GLP-1R co-agonism for weight loss, cardiometabolic health, and improvement of steatohepatitis and the latest clinical data on emerging GCGR/GLP-1R co-agonists to inform treatment strategies
- Integrate practical strategies for optimizing patient management through recognition of risk factors and referral criteria

## JOINT ACCREDITATION STATEMENT



In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is provided by Med Learning Group.

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.